Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Overhaul: The Silver Lining Amid Very Dark Cloud Of US Drug Pricing Bill

Executive Summary

Senate version of a potential drug pricing overhaul in the US includes one silver lining for manufacturers: a re-design and update of the Part D drug benefit. Is there any chance of extracting that item for the very dark clouds around it?

You may also be interested in...



President Bio-den? Executive Order Highlights Value Of Biotech – But Doesn’t Change Pricing Message

The White House is playing up a new initiative to support ‘biotechnology and biomanufacturing.’ The focus on innovation is always a welcome theme – but it does not signal any change in the emphasis on cutting drug pricing in the Biden Administration.

Pricing Reform Advocates Poised For ‘Rearguard Action’ By Industry If Legislation Prevails

Patient advocates are optimistic that ‘historic bill’ establishing price negotiation, inflation rebates and a spending cap in Medicare will pass into law.

Part D Redesign: MedPAC Finalizes Recommendations To Congress But COVID-19 Will Get In The Way

Plan includes new 30% manufacturer discount in the US Medicare Part D catastrophic phase, which manufacturers will oppose as too high. But it also caps beneficiary cost sharing, a long-sought industry goal.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel